Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Incyte Corp (INCY)

Incyte Corp (INCY)
55.00 x 5 64.00 x 1
Post-market by (Cboe BZX)
56.80 -1.41 (-2.42%) 04/21/25 [NASDAQ]
55.00 x 5 64.00 x 1
Post-market 57.00 +0.20 (+0.35%) 19:14 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
56.13
Day High
58.23
Open 57.48
Previous Close 58.21 58.21
Volume 2,158,400 2,158,400
Avg Vol 2,187,765 2,187,765
Stochastic %K 41.76% 41.76%
Weighted Alpha -4.16 -4.16
5-Day Change -0.07 (-0.12%) -0.07 (-0.12%)
52-Week Range 50.35 - 83.95 50.35 - 83.95
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,265,032
  • Shares Outstanding, K 193,524
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 61 M
  • EBITDA $ 151 M
  • 60-Month Beta 0.89
  • Price/Sales 2.63
  • Price/Cash Flow 104.28
  • Price/Book 3.23

Options Overview Details

View History
  • Implied Volatility 45.96% ( unch)
  • Historical Volatility 45.02%
  • IV Percentile 77%
  • IV Rank 61.08%
  • IV High 63.71% on 03/11/25
  • IV Low 18.10% on 05/16/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 831
  • Volume Avg (30-Day) 997
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 20,117
  • Open Int (30-Day) 24,494

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.75
  • Number of Estimates 7
  • High Estimate 1.03
  • Low Estimate 0.52
  • Prior Year 0.38
  • Growth Rate Est. (year over year) +97.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.56 +6.05%
on 04/09/25
Period Open: 61.92
63.57 -10.65%
on 04/04/25
-5.12 (-8.27%)
since 03/21/25
3-Month
53.56 +6.05%
on 04/09/25
Period Open: 73.47
76.96 -26.20%
on 02/07/25
-16.67 (-22.69%)
since 01/21/25
52-Week
50.35 +12.81%
on 04/30/24
Period Open: 52.35
83.95 -32.34%
on 11/08/24
+4.45 (+8.50%)
since 04/19/24

Most Recent Stories

More News
Incyte Earnings Preview: What to Expect

Incyte is all set to release its fiscal first-quarter earnings later this month, and analysts project a high double-digit profit growth.

XLV : 132.57 (-2.16%)
$SPX : 5,158.20 (-2.36%)
INCY : 56.80 (-2.42%)
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

NTRA : 142.23 (-3.95%)
EXAS : 43.10 (+3.66%)
INCY : 56.80 (-2.42%)
REGN : 561.49 (-0.30%)
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

NTRA : 142.23 (-3.95%)
EXAS : 43.10 (+3.66%)
INCY : 56.80 (-2.42%)
REGN : 561.49 (-0.30%)
AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes inflammation...

LLY : 818.02 (-2.61%)
INCY : 56.80 (-2.42%)
ABBV : 170.16 (-1.64%)
PFE : 22.04 (-0.45%)
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

NTRA : 142.23 (-3.95%)
EXAS : 43.10 (+3.66%)
INCY : 56.80 (-2.42%)
REGN : 561.49 (-0.30%)
Incyte Stock: Is INCY Outperforming the Health Care Sector?

Incyte has outperformed the health care sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

XLV : 132.57 (-2.16%)
ALNY : 232.75 (-0.77%)
INCY : 56.80 (-2.42%)
3 Reasons INCY is Risky and 1 Stock to Buy Instead

3 Reasons INCY is Risky and 1 Stock to Buy Instead

META : 484.66 (-3.35%)
INCY : 56.80 (-2.42%)
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

GUD.TO : 5.78 (+1.58%)
INCY : 56.80 (-2.42%)
Why Incyte Stock Was Tanking This Week

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's share...

INCY : 56.80 (-2.42%)
1 Healthcare Stock on Our Watchlist and 2 to Brush Off

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

UFPT : 210.63 (-0.20%)
LNTH : 100.62 (-0.69%)
INCY : 56.80 (-2.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 60.08
2nd Resistance Point 59.15
1st Resistance Point 57.98
Last Price 56.80
1st Support Level 55.88
2nd Support Level 54.95
3rd Support Level 53.78

See More

52-Week High 83.95
Fibonacci 61.8% 71.11
Fibonacci 50% 67.15
Fibonacci 38.2% 63.19
Last Price 56.80
52-Week Low 50.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro